Literature DB >> 34985304

Latest progress in the development of cyclooxygenase-2 pathway inhibitors targeting microsomal prostaglandin E2 synthase-1.

Krista LaBorde1, Renzhong Lu1, Ke-He Ruan1.   

Abstract

Entities:  

Keywords:  COX-2 inhibitor; anti-inflammation; inhibitor; mPGES-1; microsomal prostaglandin E2 synthase-1

Mesh：

Substances：

Year:  2022        PMID： 34985304      PMCID： PMC8905551          DOI： 10.4155/fmc-2021-0317

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


× No keyword cloud information.
  26 in total

1.  Macrophages in the Remodeling Failing Heart.

Authors:  Bijun Chen; Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2016-09-16       Impact factor: 17.367

2.  Regulation of mPGES-1 composition and cell growth via the MAPK signaling pathway in jurkat cells.

Authors:  Yi-Qing Li; Jiao-Ting Chen; Song-Mei Yin; Da-Nian Nie; Zhi-Yuan He; Shuang-Feng Xie; Xiu-Ju Wang; Yu-Dan Wu; Jie Xiao; Hong-Yun Liu; Jie-Yu Wang; Wen-Juan Yang; Li-Ping Ma
Journal:  Exp Ther Med       Date:  2018-07-30       Impact factor: 2.447

Review 3.  Identification and development of mPGES-1 inhibitors: where we are at?

Authors:  Hui-Hua Chang; Emmanuelle J Meuillet
Journal:  Future Med Chem       Date:  2011-11       Impact factor: 3.808

4.  Involvement of non-conserved residues important for PGE2 binding to the constrained EP3 eLP2 using NMR and site-directed mutagenesis.

Authors:  Annirudha Chillar; Jiaxin Wu; Shui-Ping So; Ke-He Ruan
Journal:  FEBS Lett       Date:  2008-07-22       Impact factor: 4.124

5.  Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis.

Authors:  Federica Finetti; Erika Terzuoli; Elena Bocci; Isabella Coletta; Lorenzo Polenzani; Giorgina Mangano; Maria Alessandra Alisi; Nicola Cazzolla; Antonio Giachetti; Marina Ziche; Sandra Donnini
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

6.  Engineering 'Enzymelink' for screening lead compounds to inhibit mPGES-1 while maintaining prostacyclin synthase activity.

Authors:  Diana T Ruan; Nanhong Tang; Hironari Akasaka; Renzhong Lu; Ke-He Ruan
Journal:  Future Med Chem       Date:  2021-06-03       Impact factor: 4.767

7.  DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.

Authors:  Shuo Zhou; Ziyuan Zhou; Kai Ding; Yaxia Yuan; Charles Loftin; Fang Zheng; Chang-Guo Zhan
Journal:  Sci Rep       Date:  2020-06-23       Impact factor: 4.379

8.  Mechanistic definition of the cardiovascular mPGES-1/COX-2/ADMA axis.

Authors:  Nicholas S Kirkby; Joan Raouf; Blerina Ahmetaj-Shala; Bin Liu; Sarah I Mazi; Matthew L Edin; Mark Geoffrey Chambers; Marina Korotkova; Xiaomeng Wang; Walter Wahli; Darryl C Zeldin; Rolf Nüsing; Yingbi Zhou; Per-Johan Jakobsson; Jane A Mitchell
Journal:  Cardiovasc Res       Date:  2020-10-01       Impact factor: 10.787

9.  Enhanced mPGES-1 Contributes to PD-Related Peritoneal Fibrosis via Activation of the NLRP3 Inflammasome.

Authors:  Qimei Luo; Qinghua Hu; Qingkun Zheng; Lewei Gong; Lijuan Su; Baojun Ren; Yongle Ju; Zhanjun Jia; Xianrui Dou
Journal:  Front Med (Lausanne)       Date:  2021-05-18

Review 10.  NLRP3 Inflammasome and Inflammatory Diseases.

Authors:  Zheng Wang; Simei Zhang; Ying Xiao; Wunai Zhang; Shuai Wu; Tao Qin; Yangyang Yue; Weikun Qian; Li Li
Journal:  Oxid Med Cell Longev       Date:  2020-02-17       Impact factor: 6.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.